Ixosin [E8K,E13L,S16V], Ixosin-pch

General Information


DRACP ID  DRACP02860

Peptide Name   Ixosin [E8K,E13L,S16V], Ixosin-pch

Sequence  GLHKVMRKVLGYLRNVYK

Sequence Length  18

UniProt ID  Q2LKX9 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma 24% Killing=1 µM MTT assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  HEK-293: 14% Killing=1 µM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02860

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C100H168N30O22S

Absent amino acids  ACDEFIPQSTW

Common amino acids  KLV

Mass  247809

Pl  11.15

Basic residues  6

Acidic residues  0

Hydrophobic residues  6

Net charge  6

Boman Index  -2696

Hydrophobicity  -27.22

Aliphatic Index  113.33

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  2980

Absorbance 280nm  175.29

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 27622949

Title  Central Role of the Copper-Binding Motif in the Complex Mechanism of Action of Ixosin: Enhancing Oxidative Damage and Promoting Synergy with Ixosin B

Doi 10.1021/acsinfecdis.5b00140

Year  2016

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPR_17324

DRACP is developed by Dr.Zheng's team.